Cargando…
Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
The administration of a third dose of a vaccine against SARS-CoV-2 has increased protection against disease transmission and severity. However, the kinetics of neutralizing antibodies against the virus has been poorly studied in cancer patients under targeted therapies. Baseline characteristics and...
Autores principales: | Zagouri, Flora, Papatheodoridi, Alkistis, Liontos, Michalis, Briasoulis, Alexandros, Sklirou, Aimilia D., Skafida, Efthymia, Fiste, Oraianthi, Markellos, Christos, Andrikopoulou, Angeliki, Koutsoukos, Konstantinos, Kaparelou, Maria, Gkogkou, Eirini, Trougakos, Ioannis P., Dimopoulos, Meletios-Athanasios, Terpos, Evangelos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505348/ https://www.ncbi.nlm.nih.gov/pubmed/36146552 http://dx.doi.org/10.3390/vaccines10091474 |
Ejemplares similares
-
SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
por: Terpos, Evangelos, et al.
Publicado: (2022) -
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
por: Liontos, Michalis, et al.
Publicado: (2021) -
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
por: Zagouri, Flora, et al.
Publicado: (2021) -
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021) -
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)